Biotech financing 2008: Going to a dry well in first half
America's economic malaise is dampening the ability of biotech companies to raise money from the financial markets, a traditional source of biotech capital, according to Yer Biotech Blues columnist Michael Rosen. Fortunately, something is sustaining the biotech industry, and that something is the voracious appetite...